Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court
Pharmaceutical Technology
FEBRUARY 22, 2023
Both drugs come with a high price tag. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US. Enablement as the crux of the case Amgen could win at the Supreme Court, says Shahrokh Falati, professor of law at the New York Law School.
Let's personalize your content